<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03019289</url>
  </required_header>
  <id_info>
    <org_study_id>TV7820-IMG-10082</org_study_id>
    <secondary_id>2016-001757-41</secondary_id>
    <nct_id>NCT03019289</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease</brief_title>
  <official_title>A Phase I, Open-Label, Single-Dose, Adaptive (S)-(-)-[18F]Fluspidine and [18F]Fallypride Positron Emission Tomography Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products, R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate engagement of pridopidine with S1R and D2R
      (optional) in the living human brain. No formal statistical analysis will be conducted
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Actual">January 31, 2018</completion_date>
  <primary_completion_date type="Actual">January 26, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic Assessment- Positron Emission Tomography (PET) acquisition</measure>
    <time_frame>Day 1</time_frame>
    <description>Pharmacodynamic Assessment- Positron Emission Tomography (PET) acquisition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment- maximum observed concentration (Cmax)</measure>
    <time_frame>Over 24 hour period</time_frame>
    <description>Multiple PK samples over 24 hours will be calculated for pridopidine and its metabolite TV-45065 in plasma using non-compartmental methods, when possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment- time to reach maximum (peak) concentration (tmax)</measure>
    <time_frame>Over 24 hour period</time_frame>
    <description>Multiple PK samples over 24 hours will be calculated for pridopidine and its metabolite TV-45065 in plasma using non-compartmental methods, when possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment- area under the drug concentration by time curve (AUC)</measure>
    <time_frame>Over 24 hour period</time_frame>
    <description>Multiple PK samples over 24 hours will be calculated for pridopidine and its metabolite TV-45065 in plasma using non-compartmental methods, when possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment- terminal elimination half-life (t1/2)</measure>
    <time_frame>Over 24 hour period</time_frame>
    <description>Multiple PK samples over 24 hours will be calculated for pridopidine and its metabolite TV-45065 in plasma using non-compartmental methods, when possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment- apparent volume of distribution of the drug following extravascular administration (Vd/F)</measure>
    <time_frame>Over 24 hour period</time_frame>
    <description>Multiple PK samples over 24 hours will be calculated for pridopidine and its metabolite TV-45065 in plasma using non-compartmental methods, when possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percentage of Participants with Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Health Volunteers, Huntington Disease</condition>
  <arm_group>
    <arm_group_label>pridopidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pridopidine (TV-7820) capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pridopidine (90 mg)</intervention_name>
    <description>single dose will be administered in Cohort 1. Other optional cohorts 2 and 3 may include single dose 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 22.5 mg, 45 mg, or 67.5 mg. The dose will be selected based on the results obtained from Cohorts 1 and 2.</description>
    <arm_group_label>pridopidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In general, good physical health as determined by medical history and psychiatric
             history, suicidality assessment &amp; physical examination

          -  Men who are potentially fertile (not surgically [eg, vasectomy] or congenitally
             sterile

          -  Patients with Huntington's disease (HD): diagnosis of HD and with an onset of HD after
             18 years of age

               -  Additional criteria apply, please contact the investigator for more information

        Exclusion Criteria:

          -  The subject has been previously exposed to ionizing radiation or radioactive
             substances as a result of clinical research or medical treatment in the past 10 years.

          -  The subject has a counterindication to having an MRI

          -  History of alcohol, narcotic, or any other substance dependence in the past 2 years

          -  Additional Exclusion criteria to patients with Huntington's disease:

          -  The patient has a severe motor impairment that might cause artifacts.

          -  Patients with a known history of Long QT Syndrome or a first degree relative with this
             condition.

          -  Treatment with any investigational product within 6 weeks of screening or patients
             planning to participate in another clinical study assessing any investigational
             product during the study.

               -  Additional criteria apply, please contact the investigator for more information
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>TEVA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 32648</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

